Characterization and Prediction of Natriuretic Peptide “Nonresponse” During Heart Failure Management: Results From the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP–Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) Study
Article first published online: 28 DEC 2012
© 2012 Wiley Periodicals, Inc.
Congestive Heart Failure
Volume 19, Issue 3, pages 135–142, May/June 2013
How to Cite
Congest Heart Fail.2012
- Issue published online: 3 JUN 2013
- Article first published online: 28 DEC 2012
- Manuscript Accepted: 11 NOV 2012
- Manuscript Revised: 30 OCT 2012
- Manuscript Received: 31 AUG 2012
- Cardiac Research Innovation
Figure S1. Outcomes as a function of response to guided therapy, using baseline and final NT-proBNP values. Patients finishing the trial with higher NT-proBNP values had higher event rates, irrespective of baseline value; CV, cardiovascular; NT-proBNP, N-terminal pro B-type natriuretic peptide.
Figure S2. Serial NT-proBNP in two example patients: nonresponder versus responder. A rise in NT-proBNP preceded clinical deterioration in the non-responder; CV, cardiovascular; HM II, HeartMate II; NT-proBNP, N-terminal pro B-type natriuretic peptide.
Figure S3. Cumulative hazard for first cardiovascular event in those with PROTECT risk score ≥3 compared with those with score <3. Patients with risk score ≥3 had higher cumulative hazard.
Table S1. Medications.
Table S2. Adverse events.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.